Close

Jefferies Maintains a 'Buy' on Incyte (INCY); Remain Positive On Ruxolitinib Despite NEJM Letter Oct 14, 2011 08:14AM
Jefferies Raises Price Target Incyte (INCY), Sees 56% Jul 29, 2011 12:10PM
Jefferies Remains Bullish on Incyte (INCY) Following Positive Physician Feedback on Ruxolitinib Jun 13, 2011 10:56AM
Jefferies Maintains Bullish Stance on Incyte (INCY) Following Healthcare Conference Jun 9, 2011 07:08AM
Jefferies Continues to Rate Incyte at Buy and Price Target at $25, Raises EPS Estimates Nov 10, 2010 02:00PM


Mar 23, 2010 11:15AM Jefferies & Co Maintains a 'Buy' on Incyte (INCY); Raises PT
Dec 18, 2009 09:32AM Jefferies & Co Initiates/Resumes Coverage on Pharma/Biotechnology Stocks